Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMGN NASDAQ:IBB NASDAQ:VRTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMGNAmgen$331.57+0.2%$346.62$267.83▼$391.29$178.50B0.442.73 million shs4.07 million shsIBBiShares Biotechnology ETF$167.91+2.3%$169.01$119.78▼$179.64$7.50B0.731.44 million shs1.82 million shsVRTXVertex Pharmaceuticals$430.44-0.9%$444.02$362.50▼$507.92$110.23B0.31.14 million shs1.78 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMGNAmgen+0.25%-1.45%-5.31%-11.70%+20.57%IBBiShares Biotechnology ETF+2.18%-2.75%-4.47%-4.07%+34.68%VRTXVertex Pharmaceuticals-0.89%-4.99%-1.99%-8.27%-3.74%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMGNAmgen$331.57+0.2%$346.62$267.83▼$391.29$178.50B0.442.73 million shs4.07 million shsIBBiShares Biotechnology ETF$167.91+2.3%$169.01$119.78▼$179.64$7.50B0.731.44 million shs1.82 million shsVRTXVertex Pharmaceuticals$430.44-0.9%$444.02$362.50▼$507.92$110.23B0.31.14 million shs1.78 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMGNAmgen+0.25%-1.45%-5.31%-11.70%+20.57%IBBiShares Biotechnology ETF+2.18%-2.75%-4.47%-4.07%+34.68%VRTXVertex Pharmaceuticals-0.89%-4.99%-1.99%-8.27%-3.74%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMGNAmgen 2.48Hold$355.197.12% UpsideIBBiShares Biotechnology ETF 2.73Moderate Buy$167.91N/AVRTXVertex Pharmaceuticals 2.88Moderate Buy$555.1728.98% UpsideCurrent Analyst Ratings BreakdownLatest VRTX, AMGN, and IBB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2026AMGNAmgen ArgusSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$400.00 ➝ $375.005/18/2026VRTXVertex Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C+) ➝ Buy (B-)5/14/2026AMGNAmgen Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$432.00 ➝ $427.005/13/2026AMGNAmgen Daiwa Securities GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$410.00 ➝ $390.005/7/2026AMGNAmgen Freedom CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy5/6/2026VRTXVertex Pharmaceuticals BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$607.00 ➝ $615.005/5/2026VRTXVertex Pharmaceuticals Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$612.00 ➝ $616.005/5/2026VRTXVertex Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$541.00 ➝ $543.005/5/2026VRTXVertex Pharmaceuticals Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$577.00 ➝ $572.005/5/2026VRTXVertex Pharmaceuticals Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetHold$437.00 ➝ $436.005/5/2026AMGNAmgen Erste Group BankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Hold(Data available from 5/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMGNAmgen$36.75B4.87$33.90 per share9.78$17.03 per share19.47IBBiShares Biotechnology ETFN/AN/AN/AN/AN/AN/AVRTXVertex Pharmaceuticals$12.22B8.94$17.42 per share24.71$76.29 per share5.64Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMGNAmgen$7.71B$14.3723.0714.073.3220.96%137.41%13.28%8/4/2026 (Estimated)IBBiShares Biotechnology ETFN/AN/AN/AN/AN/AN/AN/AN/AN/AVRTXVertex Pharmaceuticals$3.95B$16.8625.5322.631.8635.51%23.86%17.13%8/3/2026 (Estimated)Latest VRTX, AMGN, and IBB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/4/2026Q1 2026VRTXVertex Pharmaceuticals$4.24$4.47+$0.23$4.02$2.99 billion$2.99 billion4/30/2026Q1 2026AMGNAmgen$4.77$5.15+$0.38$3.34$8.58 billion$8.62 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAMGNAmgen$10.083.04%+8.27%70.15%14 YearsIBBiShares Biotechnology ETF$0.390.23%N/AN/AN/AVRTXVertex PharmaceuticalsN/AN/AN/AN/AN/ALatest VRTX, AMGN, and IBB DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date3/4/2026AMGNAmgenquarterly$2.523.09%5/15/20265/15/20266/5/20263/16/2026IBBiShares Biotechnology ETFQuarterly$0.12180.29%3/17/20263/17/20263/20/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMGNAmgen5.651.261.01IBBiShares Biotechnology ETFN/AN/AN/AVRTXVertex PharmaceuticalsN/A3.022.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMGNAmgen76.50%IBBiShares Biotechnology ETF62.45%VRTXVertex Pharmaceuticals90.96%Insider OwnershipCompanyInsider OwnershipAMGNAmgen0.85%IBBiShares Biotechnology ETFN/AVRTXVertex Pharmaceuticals0.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMGNAmgen31,500539.68 million535.10 millionOptionableIBBiShares Biotechnology ETFN/A45.70 millionN/AOptionableVRTXVertex Pharmaceuticals6,400253.81 million253.30 millionOptionableVRTX, AMGN, and IBB HeadlinesRecent News About These Companies31,281 Shares in Vertex Pharmaceuticals Incorporated $VRTX Bought by Fideuram Intesa Sanpaolo Private Banking S.P.A.May 20 at 3:54 AM | marketbeat.comVertex Pharmaceuticals Incorporated $VRTX Stake Raised by Atle Fund Management ABMay 20 at 3:10 AM | marketbeat.comVertex Pharmaceuticals Incorporated (VRTX) Presents at RBC Capital Markets Global Healthcare Conference 2026 TranscriptMay 19 at 5:01 PM | seekingalpha.comVertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on ItMay 19 at 3:16 PM | finance.yahoo.comVertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on ItMay 19 at 10:01 AM | zacks.comVertex Pharmaceuticals Incorporated $VRTX Holdings Decreased by Tredje AP fondenMay 19 at 6:52 AM | marketbeat.comResona Asset Management Co. Ltd. Has $40.63 Million Stake in Vertex Pharmaceuticals Incorporated $VRTXMay 19 at 6:43 AM | marketbeat.comProfund Advisors LLC Purchases 2,423 Shares of Vertex Pharmaceuticals Incorporated $VRTXMay 19 at 6:18 AM | marketbeat.comProShare Advisors LLC Grows Stake in Vertex Pharmaceuticals Incorporated $VRTXMay 19 at 6:18 AM | marketbeat.comAMF Tjanstepension AB Buys 83,487 Shares of Vertex Pharmaceuticals Incorporated $VRTXMay 19 at 3:11 AM | marketbeat.comVertex Steps Into Autoimmune Care: Mid-Stage Myasthenia Gravis Trial Shows Growing Pipeline AmbitionMay 18 at 12:50 PM | tipranks.comNorth Dakota State Investment Board Buys Shares of 8,821 Vertex Pharmaceuticals Incorporated $VRTXMay 18 at 5:49 AM | marketbeat.comCanada Post Corp Registered Pension Plan Has $2.94 Million Stake in Vertex Pharmaceuticals Incorporated $VRTXMay 18 at 3:57 AM | marketbeat.comFY2026 Earnings Estimate for VRTX Issued By Erste Group BankMay 18 at 1:23 AM | marketbeat.comLeuthold Group LLC Boosts Holdings in Vertex Pharmaceuticals Incorporated $VRTXMay 17, 2026 | marketbeat.comSTF Management LP Lowers Position in Vertex Pharmaceuticals Incorporated $VRTXMay 17, 2026 | marketbeat.comInsider Selling: Vertex Pharmaceuticals (NASDAQ:VRTX) CMO Sells $3,144,600.00 in StockMay 17, 2026 | americanbankingnews.comVertex Pharmaceuticals Incorporated $VRTX Shares Purchased by DNB Asset Management ASMay 16, 2026 | marketbeat.comVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Given Average Recommendation of "Moderate Buy" by AnalystsMay 16, 2026 | marketbeat.comAllworth Financial LP Has $6.36 Million Position in Vertex Pharmaceuticals Incorporated $VRTXMay 16, 2026 | marketbeat.comVertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitorsMay 15, 2026 | marketwatch.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVRTX, AMGN, and IBB Company DescriptionsAmgen NASDAQ:AMGN$331.57 +0.82 (+0.25%) Closing price 05/20/2026 04:00 PM EasternExtended Trading$331.25 -0.32 (-0.10%) As of 05/20/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.iShares Biotechnology ETF NASDAQ:IBB$167.91 +3.72 (+2.27%) As of 05/20/2026 04:00 PM EasterniShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc.Vertex Pharmaceuticals NASDAQ:VRTX$430.44 -3.87 (-0.89%) Closing price 05/20/2026 04:00 PM EasternExtended Trading$430.41 -0.03 (-0.01%) As of 05/20/2026 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analog Devices Provides Much-Needed Pullback: How Low Can It Go? USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook AI Consolidation Begins: Blackstone & Google Forge an AI Empire The Great AI Rotation: Cashing In on Data Mirum Pharma: A Rare Disease Growth Story to Watch Vertical Aerospace: Pre-Flight Checks Point to a Breakout HIVE Weaponizes Power for an AI Pivot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
